LLY

ACCE thesis

Eli Lilly manufactures diabetes and obesity drugs, with Mounjaro and Zepbound driving unprecedented demand for their GLP-1 receptor agonists that deliver superior weight loss results versus competitors. The company controls critical manufacturing capacity while Novo Nordisk struggles with supply constraints, creating a rare oligopoly dynamic in a $100 billion addressable market expanding beyond diabetes into broader metabolic health. Alzheimer's drug Donanemab just received FDA approval in July 2024, opening a second major growth vector after decades of failed attempts across the industry. Revenue surged 42.6% last quarter while forward PE compressed to 22x despite the stock trading near all-time highs, reflecting Wall Street's recognition that GLP-1 tailwinds have years left to run. Management raised full-year guidance three times in 2024, with Mounjaro alone generating over $3 billion in quarterly sales by Q3.

• high
  Stock above fair value

  Current price $1161.51 exceeds ACCE fair value $1050 and sits above the top of the $966-$1134 range, implying ~10% downside to fair value.
• moderate
  Elevated leverage

  Debt/Equity of 1.60 is high for a pharma compounder; limits financial flexibility if GLP-1 revenue growth decelerates.
• moderate
  Insider selling only

  Last 10 disclosed transactions show $15.75M in sales and zero buys, suggesting insiders see limited near-term upside at current prices.
• moderate
  QoQ growth deceleration

  Sequential revenue growth slowed to just +2.6% QoQ despite 55.5% YoY headline, hinting near-term momentum may be peaking.

Snapshot